KYMR vs. MRK: Kymera Therapeutics vs. Merck Stock Comparison

Company Profile

Kymera Therapeutics (KYMR) and Merck (MRK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but KYMR is classified in Biotechnology while MRK is classified in Pharmaceuticals.

Merck (MRK) has more than two decades of public-market history since January 2, 1962, whereas Kymera Therapeutics (KYMR) listed on August 21, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Kymera Therapeutics (KYMR) has an aggressive beta of 2.00, indicating higher sensitivity to broad-market moves, while Merck (MRK) is defensive at 0.11 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Merck (MRK) is heavily traded at around 10.24M shares per day, whereas Kymera Therapeutics (KYMR) sees a more moderate 833.05K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Kymera Therapeutics (KYMR) reports a negative ROE of -27.29%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Merck (MRK) reports 5.06%, ranking against industry peers normally.

Both Kymera Therapeutics (KYMR) at 0.00% and Merck (MRK) at 3.64% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Merck (MRK) reports 35.22%, ranking against industry peers normally.

Profitability Metrics

Growth

Merck (MRK) at 1.31% is around its peer norm for revenue growth, while Kymera Therapeutics (KYMR) at -16.70% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: Merck (MRK) reports EPS growth of 8.01%, ranked against its industry; Kymera Therapeutics (KYMR) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Kymera Therapeutics (KYMR) at 11.13 keeps current ratio within its industry’s typical mid-range, while Merck (MRK) at 1.35 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MRK.

Kymera Therapeutics (KYMR) at 0.05 carries an industry-typical debt-to-equity mix, while Merck (MRK) at 1.20 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Kymera Therapeutics (KYMR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Merck (MRK) reports a yield of 2.29%, ranking against industry peers normally.

Merck (MRK) reports payout ratio above 100% at 343.43%, meaning dividends exceeded current-period earnings; Kymera Therapeutics (KYMR) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Merck (MRK) trades at 148.21 times trailing earnings, ranked against its peers, while Kymera Therapeutics (KYMR) has no P/E ratio this period.

Merck (MRK) at 5.37 prices around its industry’s typical P/S ratio, while Kymera Therapeutics (KYMR) at 110.00 clears its benchmark range — KYMR looks notably rich on sales.

Both Kymera Therapeutics (KYMR) at 6.96 and Merck (MRK) at 8.06 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

Valuation Metrics